Breaking Finance News

Citigroup downgraded Illumina (NASDAQ:ILMN) from Buy to Neutral in a report released today.

Yesterday Illumina (NASDAQ:ILMN) traded 0.00% even at $184.85. The company’s 50-day moving average is $175.01 and its 200-day moving average is $156.56. The last closing price is up 18.07% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 2,633 shares of the stock traded hands, down from an average trading volume of 1,026,110

Citigroup has downgraded Illumina (NASDAQ:ILMN) from Buy to Neutral in a report released on 10/11/2016.

Previously on 10/03/2016, Vetr Inc. reported on Illumina (NASDAQ:ILMN) increased the target price from $0.00 to $198.61. At the time, this indicated a possible upside of 0.09%.

See Chart Below

Illumina (NASDAQ:ILMN)

Illumina has a one year low of $127.10 and a 52 week high of $196.47 with a P/E ratio of 63.30 ILMN’s total market value is presently $0.

A total of 19 analysts have released a research note on ILMN. Four analysts rating the company a strong buy, four analysts rating the company a buy, fifteen analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $154.53.

More About Illumina (NASDAQ:ILMN)

Illumina, Inc. (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company's products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company's customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies. It provides sample-to-answer solutions to its customers in various areas of translational and clinical genomics, such as reproductive and genetic health, and oncology. It provides reproductive-health solutions, including preimplantation genetic screening and diagnosis, noninvasive prenatal testing, and neonatal and genetic health testing. It also provides whole-genome sequencing, genotyping and NIPT services. It has operations in the United States, Europe, Asia-Pacific and other markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.